In August 2025, the United States stock market has been experiencing a mixed performance, with major indices like the Dow Jones Industrial Average and S&P 500 retreating slightly from record highs due to a pullback in tech stocks. Despite this volatility, high growth tech stocks remain an area of interest for investors seeking opportunities in sectors driven by innovation and robust demand dynamics.
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
---|---|---|---|
ADMA Biologics |
20.60% |
23.25% |
★★★★★☆ |
Palantir Technologies |
25.17% |
31.57% |
★★★★★★ |
Workday |
11.51% |
29.07% |
★★★★★☆ |
Circle Internet Group |
27.36% |
78.79% |
★★★★★☆ |
OS Therapies |
57.14% |
70.11% |
★★★★★☆ |
RenovoRx |
65.52% |
68.63% |
★★★★★☆ |
Monopar Therapeutics |
76.01% |
54.38% |
★★★★★☆ |
Gorilla Technology Group |
27.68% |
129.58% |
★★★★★☆ |
Vanda Pharmaceuticals |
22.66% |
59.11% |
★★★★★☆ |
Aldeyra Therapeutics |
42.88% |
74.81% |
★★★★★☆ |
Click here to see the full list of 68 stocks from our US High Growth Tech and AI Stocks screener.
Here's a peek at a few of the choices from the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated and metabolic diseases, with a market capitalization of $350.39 million.
Operations: Aldeyra Therapeutics focuses on developing therapies for immune-mediated and metabolic diseases. The company's market capitalization stands at $350.39 million, highlighting its position within the biotechnology sector.
Aldeyra Therapeutics, despite its current unprofitability, is poised for significant growth with an expected annual profit increase of 74.8% and revenue growth forecast at 42.9% per year, outpacing the US market average of 9.4%. Recent strategic moves include receiving EMA Orphan Designation for ADX-2191 to treat rare lymphomas and FDA Fast Track Designation for retinitis pigmentosa treatments, underscoring its focus on addressing unmet medical needs in ophthalmology. The company's innovative approach in drug development aims to optimize multiple pathways while minimizing toxicity, setting a solid foundation for future profitability and industry impact.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: TaskUs, Inc. is a company that offers outsourced digital services globally, including in the Philippines, the United States, and India, with a market cap of $1.56 billion.